menu
    • menu

    Company profile for SillaJen, Inc

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our core Phase III clinical trial in liver cancer, “PHOCUS”, is progressing efficiently. In fact, we are expecting to obtain the Futility Analysis result this year. This result holds great significance as the first clinical result from PHOCUS. At the same time, this analysis shall enhance the credibility and expectations of Pexa-Vec in the global market. This year, SillaJen was excited to have expanded the Clinical Depar...
    Our core Phase III clinical trial in liver cancer, “PHOCUS”, is progressing efficiently. In fact, we are expecting to obtain the Futility Analysis result this year. This result holds great significance as the first clinical result from PHOCUS. At the same time, this analysis shall enhance the credibility and expectations of Pexa-Vec in the global market. This year, SillaJen was excited to have expanded the Clinical Department, which will enhance our key area of focus. In order to rise to the next level, we must expand the pipeline to other tumor types.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SillaJen, Inckorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    F, 111, Hyoyeol-ro, Buk-gu, Busan, ZIP Code : 46508
    Telephone
    Telephone
    +82(51) 517-7550
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.sillajen.com/eng/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ReiThera, SillaJen Partner On SJ-600 Clinical Trial Development
    ReiThera, SillaJen Partner On SJ-600 Clinical Trial Development

    24 Jan 2025

    // CONTRACTPHARMA

    https://www.contractpharma.com/breaking-news/reithera-partners-with-sillajen-to-develop-produce-the-sj-600-series-for-clinical-trials/

    CONTRACTPHARMA
    24 Jan 2025
    Share Share
    OSR, SillaJen MOU For US Therapeutic Development
    OSR, SillaJen MOU For US Therapeutic Development

    22 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/osr-holdings-and-sillajen-have-entered-into-a-memorandum-of-understanding-to-collaboratively-pursue-the-development-of-innovative-therapeutics-and-enter-the-us-market-302123230.html

    PR NEWSWIRE
    22 Apr 2024
    Share Share
    SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
    SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC

    27 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240327409454/en

    BUSINESSWIRE
    27 Mar 2024
    Share Share
    SillaJen to acquire rights for Basilea’s novel kinase inhibitor, BAL0891
    SillaJen to acquire rights for Basilea’s novel kinase inhibitor, BAL0891

    21 Sep 2022

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=153374&sid=2

    PHARMABIZ
    21 Sep 2022
    Share Share
    Basilea announces acquisition of rights for oncology asset BAL0891
    Basilea announces acquisition of rights for oncology asset BAL0891

    19 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/20/2518805/0/en/Basilea-announces-acquisition-of-rights-for-oncology-asset-BAL0891-by-SillaJen-and-updates-financial-guidance.html

    GLOBENEWSWIRE
    19 Sep 2022
    Share Share
    SillaJen CEO detained over alleged insider trading, stoking fears of delisting
    SillaJen CEO detained over alleged insider trading, stoking fears of delisting

    12 May 2020

    // THEINVESTOE

    https://www.theinvestor.co.kr/view.php?ud=20200512000831

    THEINVESTOE
    12 May 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search